| 2026-08-11 | Press release | Q2 Q2 2026 News Release |
| 2026-08-10 | Press release | Immunic Appoints Elena Ridloff to Board of Directors |
| 2026-07-09 | Press release | Immunic to Participate in Investor Conferences in July |
| 2026-06-10 | Press release | Immunic to Participate in Investor, Industry and Scientific Conferences in June |
| 2026-06-01 | Presentation | https://ir.imux.com/image/20260601_Immunic_Company-Overview_June-2026.pdf |
| 2026-05-28 | Press release | Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Rein |
| 2026-05-27 | Press release | Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer |
| 2026-05-19 | Press release | Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors |
| 2026-05-13 | Document | Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-05-13 | Press release | Q1 2026 News Release |
| 2026-04-30 | Press release | Immunic to Participate in Investor and Medical Conferences in May |
| 2026-04-28 | Press release | Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer |
| 2026-04-23 | Press release | Immunic, Inc. Announces 1-for-10 Reverse Stock Split |
| 2026-04-09 | Press release | Immunic to Participate in Scientific and Medical Conferences in April |
| 2026-04-01 | Press release | Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement |
| 2026-03-31 | Press release | Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton |
| 2026-03-10 | Press release | Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium |
| 2026-02-26 | Press release | Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update |
| 2026-02-26 | Press release | Q4 2025 News Release |
| 2026-02-17 | Press release | Immunic Announces Closing of Oversubscribed Private Placement Financing |
| 2026-02-13 | Press release | Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial |
| 2026-02-04 | Press release | Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcin |
| 2026-01-07 | Press release | Immunic Highlights 2025 Accomplishments and Upcoming Milestones |
| 2025-11-13 | Document | Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-11-13 | Press release | Q3 2025 News Release |
| 2025-08-07 | Document | Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-08-07 | Press release | Q2 2025 News Release |
| 2024-11-07 | Press release | Q3 2024 News Release |
| 2024-11-07 | Earnings deck | Q3 2024 Earnings Call Presentation |
| 2024-08-08 | Presentation | Q2 2024 Earnings Call Presentation |
| 2024-08-08 | Press release | Q2 2024 News Release |
| 2024-05-08 | Press release | Q1 2024 News Release |
| 2024-05-08 | Presentation | Q1 2024 Earnings Call Presentation |
| 2024-02-22 | Presentation | Q4 2023 Earnings Call Presentation |
| 2024-02-22 | Press release | Q4 2023 News Release |
| 2023-11-14 | Earnings deck | Q3 2023 Earnings Call Presentation |
| 2023-11-14 | Press release | Q3 2023 News Release |
| 2023-08-03 | Press release | Q2 2023 News Release |
| 2023-08-03 | Earnings deck | Q2 2023 Earnings Call Presentation |
| 2023-05-11 | Earnings deck | Q1 2023 Earnings Call Presentation |